Abstract | Adenosine signalling has long been a target for drug development, with adenosine itself or its derivatives being used clinically since the 1940s. In addition, methylxanthines such as caffeine have profound biological effects as antagonists at adenosine receptors. Moreover, drugs such as dipyridamole and methotrexate act by enhancing the activation of adenosine receptors. There is strong evidence that adenosine has a functional role in many diseases, and several pharmacological compounds specifically targeting individual adenosine receptors -either directly or indirectly -have now entered the clinic. However, only one adenosine receptor-specific agent -the adenosine A 2A receptor agonist regadenoson (Lexiscan; Astellas Pharma) -has so far gained approval from the US Food and Drug Administration (FDA). Here, we focus on the biology of adenosine signalling to identify hurdles in the development of additional pharmacological compounds targeting adenosine receptors and discuss strategies to overcome these challenges.
. These include cardiac rhythm and circu lation 3, 4 , lipolysis 5 , renal blood flow 6, 7 , immune function 8 , sleep regulation 9,10 and angiogenesis
11
, as well as inflam matory diseases 12, 13 , ischaemia-reperfusion 14 and neuro degenerative disorders 15 (TABLE 1,2).
The possibility of therapeutically targeting adenosine receptors is clear 12, 14, 16 and has been so for a long time
. Adenosine itself is used clinically 17 (in the form of the generic drugs adenocard and adenoscan) for the treatment of supraventricular tachycardia 16, 17 , and many clinically used drugs (including dipyridamole and metho trexate) may exert their effects by altering extracellular adenosine concentrations and signalling . In addition, caffeine is used for treating premature apnoea in a clini cal setting, and many people worldwide consume caffeine on a regular basis in doses that antagonize adenosine receptors. Selective adenosine receptor agonists and antagonists are available 16 and several trials are currently in progress ( , in general the transla tion of the abundant knowledge of adenosine biology to clinical progress has been slow.
The greatest challenge in developing adenosine recep tor ligands for specific clinical applications is that adenosine signalling is so widespread. Adenosine itself is present ubiquitously, adenosine receptors are widely distributed throughout the body and adenosine acting at these receptors exerts a broad spectrum of physiological and pathophysiological functions 20 . Thus, demonstrating the effects of adenosine receptor activation or inacti vation on specific systems under distinct experimental settings is not sufficient to suggest that adenosine can be delivered in a manner that is clinically effective and safe. The complexity of adenosine signalling contributes to the sometimes debilitating side effects of adenosine receptor agonists and antagonists, and was responsible for the failure of one of the largest clinical trials for an A 1 receptor antagonist so far 21, 22 . Another challenge is that although the adenosine receptor antagonist caffeine is so commonly ingested in the normal diet, caffeine use has not been properly controlled in several previous clinical trials. In this article, we discuss the therapeutic Adenosine receptors as drug targetswhat are the challenges? fMRI-aided study of SYN115 on behaviour and brain activity in cocaine addicts
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Safety and efficacy study of SYN115 in patients with Parkinson's disease using l-DOPA to treat end of dose wearing off potential of adenosine receptor modulators, focusing on the key biological factors limiting their clinical develop ment and the hurdles that could and should be over come. The important medicinal chemistry aspects have been extensively covered elsewhere in the literature (for example, see REF. 18 ) and are thus largely omitted here.
Overview of adenosine receptors
Based on the competitive antagonism of adenosine activ ity by methylxanthines, the existence of adenosine recep tors was postulated more than 40 years ago; 20 years later, four receptors were cloned from several mammalian spe cies, including humans 1 , and identified as members of a large G protein-coupled receptor (GPCR) family 1,2 (TABLE 3) .
A 1 receptors. The A 1 receptor is the most conserved adenosine receptor subtype among species 23 , and it is widely expressed throughout the body with the highest levels found in the brain, especially at excitatory nerve endings 24 . Activation of the A 1 receptor inhibits adenylyl cyclase activity, activates potassium channels (including K ATP channels in neurons and the myocardium), blocks transient calcium channels and increases intracellular calcium and inositol1,4,5trisphosphate (Ins(1,4,5)P 3 ) levels by activating phospholipase C (PLC). A 1 receptors modulate neuronal activity by blocking neurotransmitter release and reducing the firing rate. A 1 receptors medi ate negative chronotropic and inotropic effects in the heart 25 but they also exert effects in many other organs and cells, some of which are physiologically important, as discussed below (TABLE 2) , the A 2B receptor is the most adenosineinsensitive receptor among all four adenosine receptors, requiring micro molar adenosine concentrations -which are only rarely achieved under physiological conditions. During con ditions in which adenosine levels are elevated, such as hypoxia, ischaemia or inflammation, functional roles of A 2B receptor signalling have been described in genetic and pharmacological studies; these roles include tissue adap tation to hypoxia 8, 29 , increased ischaemia tolerance 6,30 or attenuation of acute inflammation [31] [32] [33] . A 3 receptors. There is considerable variation in the phar macology and distribution -and hence function -of A 3 receptors among species. In mice, A 3 receptor sig nalling has been linked to mast cell degranulation 34 , but the situation may be different in humans. Despite the low level of A 3 receptor expression in most cells and tis sues, its expression was upregulated in blood cells from patients with rheumatoid arthritis, Crohn's disease 35 and colon cancer 36 when compared to healthy individuals, correlating with the upregulation of nuclear factorκB (NFκB) signalling and the phosphoinositide 3kinase (PI3K)-PKB-AKT signalling pathways. Indeed, pre clinical studies have demonstrated antiinflammatory, anticancer and cytoprotective effects of A 3 receptor ago nists 37 (as discussed below).
Sources of adenosine
Adenosine is the only important agonist for the three key adenosine receptors -A 1 , A 2A and A 2B -and the major, full agonist ligand for the A 3 receptor (for which inosine is an incomplete agonist). The concentration of adenosine in the extracellular compartment is the consequence of many biological processes, including extracellular adenosine production, adenosine trans port, adenosine formation from intracellular adenosine sources (for example, via the Sadenosylhomocysteine pathway) and adenosine metabolism to inosine or AMP (see FIG. 1 ; upper panel). Extracellular adenosine comes from two sources. First, it may be derived from the external transport of intra cellularly generated adenosine. However, adenosine is involved in several different metabolic pathways, and its intracellular concentration can never be zero. Therefore, most -if not all -cells possess equilibrative adenosine transporters, which allow adenosine to quickly cross the cell membrane 38 . Consequently, there will be -by neces sity -a finite level of adenosine in the extracellular space, even under the most basal conditions. From the baseline level, adenosine concentrations can increase substantially. Notably, very minor changes in steadystate ATP levels in the cell (normally ~5 mM) will translate into major changes in intracellular adenosine concentrations (nor mally around 100,000 times higher). Second, extracellu lar adenosine may also be formed from the extracellular hydrolysis of adenine nucleotides. In many instances, extracellular adenosine is derived from the breakdown of extracellular nucleotides, particularly ATP and ADP. The generation of extracellular adenosine from ATP is predominantly controlled through a twostep enzy matic reaction: first, the conversion of ATP or ADP to AMP by ectonucleoside triphosphate diphosphohydrolase 1 (ENTPD1; also known as CD39), which is followed by AMP hydrolysis to adenosine by ecto-5′-nucleotidase (NT5E; also known as CD73).
ATP can be released from various cell types by multiple mechanisms: it can be coreleased from storage vesicles together with other hormones (such as neurotransmit ters), it can be released via a 'kiss and run' mechanism 39 (a type of synaptic vesicle release where the vesicle opens and closes transiently) or it can be released from the lysosome by exocyotosis 40 . ATP release mechanisms
Methylxanthines
Purine derivatives with a common xanthine core molecule and methyl group attached in various combinations to nitrogens. The most common methylxanthines include caffeine, theophylline, theobromine and paraxanthine.
G protein-coupled receptor (GPCR). A cell membrane protein characterized by a seven-transmembrane structure, which is coupled to trimeric G proteins; GPCRs elicit diverse sets of signalling and biological functions.
Ectonucleoside triphosphate diphosphohydrolase 1 (ENTPD1; also known as CD39). A membrane-bound enzyme with enzymatic activity in the extracellular space; ENTPD1 catalyses the conversion of extracellular ATP and/or ADP to AMP -an important step in generating extracellular adenosine.
Ecto-5′-nucleotidase (NT5E; also known as CD73). A membrane-bound enzyme with enzymatic activity in the extracellular space; NT5E catalyses the conversion of extracellular AMP to adenosine, thereby functioning as a pacemaker enzyme for generating extracellular ATP-derived adenosine.
include uncontrolled leakage from necrotic cells 4 , leak age from cells undergoing other forms of cell death, controlled release through pannexin hemichannels 41, 42 as well as release from inflammatory cells or vascular endothelia through connexin hemichannels and chan nels such as P2X purinergic receptor 7 (REFS 43-45).
The basal physiological level of extracellular adeno sine from both sources has been estimated to be in the range of 30-200 nM 46 . The processes that lead to increased intracellular adenosine formation often affect several cells or a whole tissue, thereby causing consid erably widespread and enduring changes in adenosine concentration. By contrast, the release of adenine nucleo tides may be limited in quantity and spatially restricted. Thus, the two modes of changes in adenosine concentra tion can have considerably different consequences.
Adenosine receptor functions
Adenosine receptors have been implicated in several key physiological processes, ranging from neuromodulation to immune regulation, and from vascular function to metabolic control. Adenosine has been postulated to have a role as a danger signal involved in homeostasis.
One approach that has proved to be particularly effective in uncovering the normal physiological roles of adeno sine receptors is genetic knockout. Genetic knockout mouse models for all four adenosine receptors (Adora1, Adora2a, Adora2b and Adora3, which encode A 1 , A 2A , A 2B and A 3 receptors, respectively) have now been generated by the targeted deletion of either of the two critical exons of the adenosine receptors 20, 47 . Although detection of the pathophysiological roles of adenosine signalling has been more difficult, as this requires mod els of disease in the genetically modified organism, the available genetic knockout mouse models have provided some insights. A list of some of the key physiological and pathophysiological roles of the adenosine receptors (derived mainly from studies with genetic knockout models) is given in TABLE 2, and some of these roles are discussed in more detail below.
Two lines of Adora1knockout mice have been gen erated 7, 48 , and Adora1knockout mice exhibit decreased fertility, a significant decrease in lifespan 49 and an increased risk of seizures 48 . In the kidney, knockout studies have confirmed the pharmacological finding that stimulating the A 1 receptor on the glomerular afferent arteriole reduces renal blood flow and the glomerular filtration rate, and stimulation of the A 1 receptor on the proximal tubules increases sodium and water reabsorp tion 7 . These studies provide the rationale for developing A 1 receptor antagonists to control renal dysfunction in patients with acute heart failure.
A 2A receptors are expressed at high levels in the dorsal striatum, a critical basal ganglia structure involved in motor control, where they are colocalized with dopa mine D 2 receptors; they inhibit D 2 receptor binding in the striatum and immediateearly gene expression [50] [51] [52] . The behavioural actions of A 2A receptor antagonists partly overlap with those of D 2 receptor agonists, which has implications for the treatment of Parkinson's disease (as discussed below) and also influences working mem ory 53, 54 , reversal learning 53 and goaloriented behaviour 55 , while leaving spatial reference memory, motor function and anxietylike behaviours intact.
Three strains of Adora2aknockout mice have been generated (Adora2a knockout in CD1 mice 56 , in mixed 129sv mice crossed with C57BL/6 mice 57 and in con genic C57BL/6 mice 58 ). Adora2aknockout mice exhibit reduced exploratory behaviour and score higher in anxiety tests, with male mice being much more aggres sive towards intruders 56 . Because of their reduced activity they gain weight, especially in the form of fat. Their response to acute pain stimuli is slower and their blood pressure and heart rate are elevated 56 . Genetic Adora2aknockout models have uncovered complex roles of the A 2A receptor in tissue protection: that is, A 2A receptor activation confers tissue protection in periph eral organs 59, 60 , whereas its inactivation confers neuro protection against brain injury 57, 61, 62 . Genetic knockout models have shown that both A 1 and A 2A receptors are involved in mediating the sleeppromoting proper ties of adenosine in the brain 63 . Moreover, the arousal effects of caffeine seen in wildtype animals are blunted in Adora2aknockout mice 10 . It is therefore conceivable that adenosine receptor ligands could be used as normal cognitive enhancers or sleep promoters.
Several strains of Adora2bknockout mice have also been generated 64, 65 . Given that A 2B receptors are generally
Box 1 | History of adenosine receptor targeting
More than 80 years ago, extensive studies on the actions of adenosine reported profound cardiac effects, vasodilation and a marked lowering of body temperature 253, 254 . It was proposed that different forms of tissue trauma could release adenosine and/or AMP that could cause vasodilation 253 . Subsequently, the administration of adenosine derivatives was found to have a protective effect 255 . During the Second World War there was interest in the use of such derivatives in the clinic. A relationship was found among the severity of the trauma, the magnitude of the loss of tissue adenine nucleotides and the release of breakdown products. By the mid-1960s it was concluded that the protective effect of adenosine derivatives in the prevention of irreversible trauma may be attributed to vasodilation, energy transfer, anticoagulation or a combination of these mechanisms 256 . The anticoagulatory effect is now attributed to the actions of adenosine on platelet adenosine receptors to reduce their activation 56, 257 . The second possibility -that adenine nucleotides enter cells to restore energy charge -is no longer credible. The vasodilatory effect, which was first suggested by Bennet and Drury 253 , was followed up in detail 30 years later 258, 259 when it was demonstrated that a lack of energy owing to hypoxia caused the breakdown of myocardial adenine nucleotides, and that the breakdown products were able to cause coronary vasodilation. This led to the very attractive hypothesis that adenosine is a -or themediator of hypoxic vasodilation. Indeed, adenosine could be increasing oxygen supply to an energy-depleted tissue, thereby subsequently limiting its own formation -a classical tenet of homeostasis and negative feedback.
The studies on the effects of adenosine on the heart were also very important in demonstrating that methylxanthines such as theophylline acted as adenosine antagonists 1 . They also established the use of adenosine uptake inhibitors such as dipyridamole as tools in adenosine research 260 . It is now believed that adenosine contributes to basal coronary tone, but has only a minor role in increasing coronary blood flow during exercise 261 , and appears to be a very important factor in pathophysiological conditions including ischaemia 6 and ischaemic preconditioning 30,65,262
. The rapid breakdown of adenosine in the bloodstream was useful in the development of adenosine as a diagnostic tool or a therapeutic agent in supraventricular tachyarrhythmia 17 . Rapid adenosine removal was, however, a disadvantage in other potential applications; efforts to synthesize more stable analogues started in the 1960s, yielding the adenosine analogue 2-chloroadenosine, N6-phenylisopropyl adenosine (R-PIA) and N-ethyl-carboxamido adenosine (NECA). The somewhat different effects of these compounds helped to define the subtypes of adenosine receptors, but all of these compounds exhibited so many effects that their development for therapy proved difficult. In the 1970s it became clear that there are receptors for adenosine, and there was evidence that methylxanthines such as caffeine and theophylline produce many of their actions by acting as antagonists at adenosine receptors. Gradually it also became clear that some drugs with an unknown mechanism of action (for example, dipyridamole and methotrexate) probably acted, at least in part, by increasing the levels of adenosine and the stimulation of adenosine receptors. Towards the end of the twentieth century it became clear that there are subtypes of adenosine receptors, and we now recognize a family of four adenosine receptors that are present in most vertebrates. All of these developments strongly suggest that adenosine receptors are druggable.
Acute heart failure
A gradual or rapid change in the signs and symptoms of heart failure. Many pathological factors, including worsening renal function, persistent neurohormonal activation and progressive deterioration in myocardial function, all contribute to the development of acute heart failure.
Parkinson's disease
A neurodegenerative disease characterized by the loss of dopaminergic neurons in the substantia nigra pars compacta of the midbrain and the accumulation of proteinaceous intracellular inclusions (Lewy bodies), leading to decreased dopamine levels in the striatum and cardinal motor symptoms.
Ischaemic preconditioning
A phenomenon in which repeated short periods of exposure to sublethal ischaemia induce tolerance and protection against subsequent lethal ischaemic injury.
only expressed at low levels and they typically exhibit low affinity for adenosine in most assays 66 , it is sur prising that Adora2bknockout mice have very strong phenotypes, especially in relation to the vasculature 64 . Adora2bknockout mice show lowgrade inflamma tion of the vasculature at the baseline 64 and suffer from increased vascular leakiness in several organs 29 . A major reason for this could be that local adenine nucleotide signalling is very important in this compartment and thus adenosine levels can locally and transiently be con siderably high 29 . Moreover, an increased susceptibility to ischaemic and inflammatory injuries is typically observed in the intestine 67 , liver 68 , kidney 6, 69 , lung 70 and heart 30,65 of Adora2bknockout mice, with conditions characterized by elevations in extracellular adenosine lev els. Under such conditions, studies in Adora2bknockout mice have shown that A 2B receptor signalling is impli cated in attenuating hypoxiadriven inflammation and in the adaptation of tissues to conditions of limited oxygen availability.
Conversely, activation of the A 2B receptor has been shown to promote bone cell differentiation 71, 72 , control glucose homeostasis 73 and regulate hyperlipidaemia and atherosclerosis 74 . However, some harmful effects of A 2B receptor activation have also been reported -includ ing promotion of tumour growth in the bladder and breast 75 , renal fibrogenesis 76 and inflammatory damage -in an experimental autoimmune encephalomyelitis (EAE) model of multiple sclerosis 77 . It is crucial to clarify whether these different and often opposing biological effects of the A 2B receptor, as revealed by these knockout mouse models, are in part attributed to the confounding effect of different genetic backgrounds, developmental compensation or distinct biological effects under patho logical conditions. Similarly, knockout of the A 3 receptor in mice was surprising, resulting in marked phenotypes even at loca tions where the receptors are very sparse (for example, the brain) and where antagonists (or agonists) have little effect 78, 79 . The reason for this remains unknown, but a possible developmental role for A 3 receptors has been postulated 78 . Mice deficient in the genes encoding ENTPD1 or NT5E (enzymes that mediate the genera tion of extracellular adenosine from ATP) also appear to be healthy and reproduce normally in a pathogenfree environment, but they have subtle defects in the vascular barrier function of several organs 80, 81 . Entpd1knockout mice have a prolonged bleeding time owing to a defect in their platelet function, which does not appear to be asso ciated with a change in adenosine receptor signalling; rather, it appears to be related to desensitization of P2Y purinergic receptor 1 (caused by elevated ATP levels) through which adenine nucleotides signal and which is crucial for platelet activation 104 . Together, these findings in Adoraknockout mice as well as Entpd1 and Nt5eknockout mice indicate that longterm treatment with antagonists should be toler ated without having very serious consequences. The relatively minor differences between adenosine receptor knockout mice and wildtype mice under physiological conditions could theoretically be due to major com pensatory changes. Although there is little evidence for the existence of such compensatory changes (TABLE 3) , it should be acknowledged that this has not yet been systematically examined. For example, studies in mice with concomitant deletion of all four adenosine recep tors have not been yet published; it would be interesting to see whether these mice are viable and whether they show a phenotype at the baseline.
Adenosine signalling in pathological conditions
Adenosine signalling is not very prominent under physio logical conditions in most tissues, but aberrant adenosine signalling has been implicated as a common disease mechanism underlying inflammatory and ischaemic tissue damage 3, 59, 82, 83 . This includes excessive inflamma tory tissue damage such as that seen in acute liver injury, ischaemic kidney injury, acute lung injury, traumatic brain injury, ischaemic brain injury, epilepsy and certain neurodegenerative disorders such as Parkinson's dis ease and Huntington's disease 20,61,84 . As such, enhanced adenosine signalling is essential for the resolution of these pathological conditions associated with tissue inflamma tion and remodelling. 
Adenosine kinase
An enzyme that converts intracellular adenosine to AMP, which is critically important in setting the basal adenosine level. Hypoxia is associated with transcriptional repression of adenosine kinase, thereby resulting in increased intracellular adenosine levels and enhanced extracellular adenosine signalling.
Adenosine levels. Intracellular adenosine formation is increased whenever ATP consumption exceeds ATP syn thesis, which consequently leads to an increase in levels of AMP -the precursor of adenosine. ATPdependent adenosine signalling occurs typically during conditions that are associated with the release of ATP from intra cellular stores, and can occur during injurious condi tions such as ischaemia and reperfusion 14 , the extracellular concentration of adenosine is the sum of many biological processes, excluding intracellular adenosine production. Adenosine is transported via equilibrative nucleoside transporter 1 (ENT1) and other transporters. ATP is released via multiple processes. ATP is converted to adenosine by ectonucleoside triphosphate diphosphohydrolase 1 (ENTPD1; also known as CD39) and ecto-5′-nucleotidase (NT5E; also known as CD73). Adenosine is metabolized to inosine, AMP or S-adenosylhomocysteine (SAH). Many cell types perform all the biological processes displayed in the figure, but some cells show only a limited repertoire. Under pathological conditions (lower panel), local adenosine signalling is markedly amplified in response to insults and hypoxia by a surge in extracellular adenosine concentration from the baseline (20-300 nM) to up to 30 μM in ischaemic or hypoxic tissues. There is also a parallel marked induction of enzymes that are responsible for ATP-dependent adenosine signalling as well as adenosine receptor expression (particularly A 2A and A 2B adenosine receptors) and the suppression of enzymes involved in adenosine metabolism, such as adenosine kinase (AK). Adenosine signalling under pathological conditions is controlled by the following factors: increased extracellular adenosine levels by ATP release; induction of ENTPD1 expression by the transcription factor SP1 and of NT5E expression by hypoxia-inducible factor-1α (HIF1α); induction of A 2A receptor expression by HIF2α and of A 2B receptor expression by HIF1α; repression of AK by HIF1α and suppression of ENT1 or ENT2 activity by HIF1α. ADA, adenosine deaminase; cAMP, cyclic AMP; ERK, extracellular signal-regulated kinase; MAPK, mitogen-activated protein kinase; PKA, protein kinase A.
is accompanied by increased levels of local inflam matory cytokines such as interleukin1β (IL1β) and tumour necrosis factor (TNF), which leads to a delayed (~24hour), marked and sustained increase in adeno sine receptor expression on tissues and inflammatory cells 32, 33, 85 . Indeed, many studies have demonstrated that cellular responses to hypoxia are characterized by robust increases in extracellular adenosine production 80, 86 and signalling events through adenosine receptors 3 . Several studies have indicated that extracellular aden osine levels can rise from the baseline (20-300 nM) 42, 46, [87] [88] [89] to the low micromolar range in conditions of extreme physiology such as strenuous exercise or subsistence at high altitude and hence low ambient oxygen levels 46, 87, 88 . In ischaemic areas or after massive tissue trauma leading to cell death by necrosis, extracellular adenosine levels can increase to ~30 μM [88] [89] [90] . As noted above, this increase could be due to increased intracellular formation of adenosine or to increased release of nucleotides. Recent research has focused on the latter possibility.
Although the ability of adenosine to stimulate aden osine receptors is dependent on the number of adeno sine receptors 2, 15, 91 , and this number can change (that is, increase) under some circumstances (see below), it is more likely that an increase in adenosine receptor sig nalling in pathological conditions largely depends on increased levels of adenosine. Numerous reports have indicated that increased ATPdependent adenosine sig nalling (for example, as a result of hypoxia exposure, acute inflammation, and so on) can profoundly alter dis ease susceptibility in both animal models of disease and patients 4, 92 .
Adenosine receptor expression and activity. Together with dramatic increases in extracellular adenosine levels, conditions of tissue hypoxia are associated with enhanced expression of adenosine receptors -par ticularly the A 2A receptor 93 102 or dendritic cells 296 has been implicated in the attenuation of organ injury during hepatic or renal ischaemia, respectively.
The complex interplay between adenosine and adenine nucleotide signalling is highlighted in ENTPD1deficient mice; these mice not only have elevated circulating nucleotide levels and related pathology 104, 105 but also a deficiency in extracellular adenosine signalling, which is associated with increased vascular leakage during hypoxia 80 , or more severe tissue injury during lung inflammation or ischaemia and reperfusion [96] [97] [98] [99] 106, 107 . In addition, protective and antiinflammatory adenosine signalling against ischaemic and inflammatory injury is absent in the heart 65 , lung 106 , liver 100 , kidney 108 , intestine 31 and blood 109 121, 122 and spinal cord injury 123 . Moreover, ADORA3 mRNA expression is upregulated in hepatocellular carcinoma tissues in comparison with adjacent normal tissues 124 and is also upregulated in peripheral blood mononuclear cells (PBMCs) derived from patients with hepatocellular carcinoma compared to healthy individuals 36 ; this indi cates that the A 3 receptor in PBMCs may be a potential biomarker of hepatocellular carcinoma, reflecting the A 3 receptor status in remote tumours.
Several transcriptional mechanisms contribute to the induction of A 2A receptor, A 2B receptor and ecto nucleotidase expression in response to stress, hypoxia and inflammation and other pathological insults as well as a local increase in adenosine levels. Hypoxia is asso ciated with a transcriptional programme that results in the induction of ENTPD1 (REFS 80, 96, 97, 99) and NT5E 31,65,81,106 , thereby elevating the capacity of differ ent tissues for extracellular adenosine production 13,14 . Moreover, ENTPD1 and NT5E have been implicated in the conversion of ATP and ADP to adenosine on regu latory T cells, thereby providing an autocrine feedback loop to enhance the antiinflammatory functions of this subset of T cells 125 .
Other studies have provided evidence that hypoxia also attenuates extracellular adenosine uptake [126] [127] [128] and its subsequent metabolic breakdown in the intracellular compartment, through the activity of the transcription factor hypoxia-inducible factor (HIF) 129, 130 whereas transcriptional pathways under the control of HIF have been described for the induction of the A 2A receptor 93 and A 2B receptor 31, 80, 94, 95 . Similarly, in T cells, a system involving the regulation of adenosine, haem oxygenase 1, carbon monoxide and the A 2A receptor leads to resolution of the inflammatory response 132 . The adenosine signal is amplified through a feedforward mechanism with both a surge in extracellular ATP and/ or adenosine and the coordinated induction of the A 2A receptor by local inflammatory cytokines.
Knockout studies have revealed that IL6 is crucial in mediating A 1 receptor upregulation to amplify the A 1 receptormediated protection against PTZinduced seizures 112 . Interestingly, extracellular ATP and adeno sine signalling frequently control opposing biological effects 133, 134 but they can also act synergistically 43 . Hypoxia shifts the balance from ATP towards adenosine signal ling by enhancing the hydrolysis of adenosine precursor nucleotides. This shift from ATP towards adenosine signalling involves: increased extracellular adenosine levels by ATP release; induction of ENTPD1 expression by the transcription factor SP1 and of NT5E expression by HIFα; induction of A 2A receptor expression by HIF2α and of A 2B receptor expression by HIF1α; inhibition of adeno sine kinase activity by HIF1α; and suppression of ENT1 or ENT2 activity by HIF1α 3 (see FIG. 1 ; lower panel).
Targeting adenosine receptors
Numerous articles have indicated the potential of adeno sine receptors as therapeutic targets 3,12,16,135 . The intro duction of useful radioligands for adenosine receptors has aided the drug discovery process. Over the past 20 years, medicinal chemistry efforts have generated agonists and antagonists with high affinity (a dissocia tion constant (K d ) at low nanomolar concentrations) and high selectivity (>100 to 200fold higher than other adenosine receptor subtypes) for the human variants of each of the four receptors 1 . Moreover, both agonist and antagonist ligands containing positronemitting radio isotopes have been developed to monitor the in vivo occupancy of adenosine receptors in humans 18 . As such, the lack of selective ligands is not a limiting factor for research and drug development on adenosine receptors, as has been the case for some other GPCRs. Moreover, there are continued medicinal chemistry efforts to develop novel adenosine ligands with refined structureactivity relationships, improved in vivo biodistribution and tissue selectivity, which is crucial to druggability (reviewed in REF. 18 ).
A bigger problem is the broad distribution of the receptors, and a possible approach for achieving tissue selectivity could be the use of partial agonists that would predominantly act where there is a high number of so called 'spare' receptors. For example, it is well known that adipocytes have a large 'receptor reserve' , and par tial A 1 receptor agonists might therefore selectively activate those A 1 receptors 136 . Based on decades of pre clinical studies, there have been numerous attempts to develop drugs and many clinical trials are now under way; for some recent examples, see Chronic heart failure. Impaired renal function is com mon in patients with acute heart failure; it directly con tributes to deterioration of the heart and is associated with an adverse outcome, including increased mortality. Local adenosine production in the kidney is increased in patients with heart failure as a result of hypoxia caused by reduced renal perfusion and by stimulation with diuretics 142 . Based on our understanding of the mechanisms associated with renal dysfunction and the demonstrated control of renal function via A 1 recep tors, A 1 receptor antagonists were developed. These antagonists reduced the risk of persistent worsening renal failure by >50% in a Phase IIb study involving 301 patients with acute heart failure, and improved renal plasma flow in 63 ambulatory patients with chronic heart failure 143 . Based on these promising results, a placebocontrolled, randomized Phase III trial involving 2,033 patients with acute heart failure (the PROTECT study) was carried out with the A 1 receptor antagonist rolofylline; this was the largest study to date involving the use of A 1 receptor antagonists to target renal function. Unfortunately, the results were disappointing and rolofylline did not pre vent persistent worsening renal function 21, 144 . The reason for this absence of renoprotective effects is likely to be due to an enhanced diuretic effect (as evident by more pronounced weight loss) in the rolofylline group, which may have offset the effects of rolofylline on the pres ervation of renal function 22 . Moreover, pharmacologi cal and genetic studies have clearly demonstrated that A 1 receptors mediate protective effects against ischaemic kidney injury and brain injury, which is consistent with the increased frequency of stroke and seizure activity in clinical trials of A 1 receptor antagonists 22 . Thus, the development of A 1 receptor antagonists for the treatment of disorders associated with impaired fluid retention, such as congestive heart failure, should proceed with caution.
Inflammatory diseases, autoimmune disorders and cancer. Given the high levels of expression of all four subtypes of adenosine receptors in cells of the immune system and the dynamic modification of their expression within inflammatory and tumour environments, A 1 , A 2A , A 2B and A 3 receptors are being actively pursued as thera peutic targets for autoimmune diseases, chronic inflam matory disorders and cancer 145 . For example, based on preclinical pharmacology and encouraging safety data in Phase I studies, the A 3 receptor agonists CF101 (also known as IBMECA) and CF102 have been tested in several Phase II trials for rheumatoid arthritis 146 . CF101 treatment was associated with a 20% improvement in disease symptoms according to the classification of rheu matoid arthritis responses by the American College of Rheumatology. Based on anecdotal findings from this trial indicating that CF101 also improved indicators of dry eye syndrome, a followup Phase II trial (randomized, doubleblind and placebocontrolled) was carried out, which determined that CF101 improved the clearance of corneal staining, tear breakup time and tear meniscus height 147 . Notably, orally administered A 3 receptor ago nists (given at doses that are effective for treating dry eye syndrome) do not cause cardiovascular and other side effects 147 . The efficacy and safety of CF101 was also tested in a Phase II trial of moderate to severe chronic plaque type psoriasis 37 ; it was found to be effective and thus advanced to Phase III trials for these indications as an antiinflammatory agent. In addition, active Phase II clinical trials are underway to test the efficacy of A 3 receptor agonists for the treatment of hepatocellular car cinoma and hepatitis 37 . Furthermore, experimental stud ies in mice suggest a possible use of A 3 receptor agonists in suppressing melanoma growth by inducing T cell mediated adoptive immunity 148 and in the control of chronic neuropathological pain 37, 149 . These therapeutic effects of CF101 are believed to be mediated by its inhibi tion (via cAMP and calcium signalling) of the oxidative burst and its antiinflammatory activity 150 . However, it should be noted that both proinflammatory and anti inflammatory effects of A 3 receptor activation have been demonstrated, depending on the cell type and animal species being studied 151 .
Sickle cell disease. Patients with sickle cell disease have periodic episodes of vasoocclusive crisis and, in some cases, lifethreatening pulmonary vasoocclusion. Histori cally, microvascular occlusion was attributed to rigid sickled erythrocytes. Recently, ischaemia-reperfusion injury with resultant white cell activation has been impli cated as a crucial contributor to the pathophysiology of sickle cell disease 152 . Like ischaemia-reperfusion injury, sickle cell disease is associated with increased levels of adenosine. An experimental study has provided strong evidence that A 2B receptor activation on erythrocytes promotes sickling in patients with sickle cell disease 153 . However, treatment with an A 2A receptor agonist has been indicated to attenuate sterile inflammation and T cell activation in this disorder 152 . A clinical trial in patients with sickle cell disease is currently being conducted using the FDAapproved A 2A receptor agonist regadenoson (ClinicalTrials.gov identifier: NCT01085201) 154, 297 . Thus, different adenosine receptors (A 2A or A 2B receptors) can mediate opposing effects in a single disease 155 -a finding that may be of considerable significance when developing adenosine receptortargeting agents.
Challenges in targeting adenosine signalling
Despite the clear potential of adenosine receptors as therapeutic targets, only one agent has so far reached the clinic. From a medicinal chemistry perspective, standard pharmacological assays of selectivity and efficacy may not provide sufficient information on the different bio distribution and pharmacokinetics of adenosine ligands with subtle structural differences. Understanding differ ences in local drug distribution are important for the prediction of potential side effects, given the ubiquitous presence of adenosine and the widespread distribution of its receptors. Despite the large numbers of selective adenosine receptor agonists and antagonists reported in the literature, the clinical application of adenosine ligands is lacking. Below, we discuss the various challenges that are likely to be hampering the success of drugs targeting adenosine receptors. Measurement of adenosine levels. As mentioned above, determining the local levels of adenosine is crucial to understanding its biology and pharmacology. Therefore, the fact that local adenosine concentrations rapidly fluc tuate and are difficult to measure represents a major chal lenge for this field. Direct biosensorbased measurements of adenosine and microdialysis probes coupled with electrochemical detectors are commonly used to probe or sample the extracellular concentration of adenosine and various bodily fluids in different tissues under phys iological and pathological conditions 156 . However, the microdialysis technique is known to destroy some cells when the probe is inserted into a tissue, which results in the release of ATP that is converted to adenosine, thereby elevating local adenosine levels. In addition, when the microdialysis probe is left in a tissue for an extended period of time, it is covered by cells such as glial cells, which metabolize adenosine and reduce adenosine levels before they can be measured.
Moreover, adenosine can be very rapidly formed during sampling -for example, the ATP hydrolysis that occurs when a tissue is extracted generates much higher levels of adenosine in a few seconds than were initially present. Thus, adenosine levels can only be accurately determined in tissues via the freezeclamping tech nique, but this obviously precludes any finer structural resolution. When sampling blood, it is difficult to avoid platelet destruction and the subsequent release of ADP and ATP, which are rapidly broken down to adenosine. This means that the accurate determination of adeno sine levels locally under physiological and pathophysio logical conditions rarely occurs, and unfortunately the literature is replete with incorrect estimates.
Another major challenge relates to the difficulty in distinguishing between the various sources of extracellu lar adenosine under physiological and pathological con ditions. For example, despite excellent evidence that ATP released from astrocytes is an important signal under numerous circumstances 39 , a recent study provides com pelling evidence that neuronal adenosine release -and not astrocytic ATP release -mediates feedback inhibi tion of excitatory activity in seizure models 157 . Therefore, to determine the unique adenosine signals (and there fore adenosine receptors) that are associated specifically with disease status, it is crucial to develop strategies that are capable of detecting and characterizing the changes in extracellular adenosine levels in different definable extracellular domains within the brain parenchyma (that is, neuronal and/or synaptic, astrocytic, microglial or vas cular domains).
Measurement of the number of adenosine receptors.
Although we do not know how receptor distribution in patients varies in different diseases, recent studies indi cate that this could potentially be studied by monitoring receptors using in vivo imaging methods. . These A 2A receptor ligands will probably also be very useful in the direct assessment of drug-A 2A receptor interactions in disease pathogenesis and the development of unwanted side effects. They should also aid in improv ing the design of clinical trials of A 2A receptor antagonists for Parkinson's disease, as one would be able to adequately monitor receptor occupancy over time. In addition, as A 2A receptor expression in human tissues has been shown to correlate with disease progression, such as in Huntington's disease 160, 161 , these ligands may be used as potential bio markers to monitor the disease course during clinical trials. Furthermore, PET ligands for other adenosine receptors could be used to monitor disease progression in ischaemia and cancer by assessing the expression of adeno sine receptors in patients suffering from these conditions.
Complexity of adenosine signalling during disease course. In acute injury settings, hypoxiadriven eleva tions in extracellular adenosine levels activate pathways that promote tissue adaptation to conditions of limited oxygen availability and dampen hypoxiadriven inflam mation 13, 15 . These pathways include those involved in restoring normal oxygen levels 153 , enhancing metabolic ischaemia tolerance 30 and dampening hypoxiainduced inflammation 3, 8, 82 . Indeed, preclinical studies have shown that adenosine signalling is beneficial in acute injury of the lungs 70, 162 and ischaemic injury of the kidneys 69,60 , the heart 65 , the gastrointestinal tract 163 and the liver 164 . However, if elevated adenosine levels are sustained beyond the acute injury phase, hypoxic adenosine responses can become detrimental owing to the activation of pathways that promote tissue injury and fibrosis 165 . For example, chronic elevations of adenosine levels during hypoxia can contribute to tissue fibrosis in different organs, including the lungs 166, 167 , liver 168 , skin 169 and penis 170, 171 . Therefore, under conditions of chronically elevated adenosine levels, blockade of adenosine signalling appears to be beneficial.
An interesting example of the opposing effects of adenosine signalling in a single disease model comes from studies of bleomycin-induced lung injury. Studies in Nt5eknockout mice 172 , which are unable to convert extra cellular AMP to adenosine and thus develop a more severe degree of lung injury during the acute phase of bleomycin induced lung disease, have shown that extracellular aden osine production is implicated in lung protection during acute lung injury. Subsequent studies in other models of lung injury -such as ventilatorinduced lung injury 70 , lipopolysaccharideinduced lung inflammation 32 or lung inflammation in adenosine deaminasedeficient mice 173 -have implicated A 2B receptor signalling in adenosine dependent protection from acute lung injury 92 . However, there is contrasting evidence that A 2B receptor signal ling can be detrimental in more chronic forms of lung injury 174 . As such, there were substantial reductions in pulmonary fibrosis in mice following the genetic removal of Adora2b (which encodes the A 2B receptor) during the chronic phase of bleomycininduced lung injury, which indicates a profibrotic role for this receptor. These studies highlight the opposing roles of A 2B receptor signalling during acute versus chronic stages of bleomycininduced lung injury 175 .
Bleomycin-induced lung injury
A widely used antitumour agent causing single-and double-stranded breaks in cellular DNA, leading to genomic instability of damaged cells. Bleomycin induces apoptosis and increases the production of reactive oxygen species, resulting in oxidative stress and pulmonary fibrosis.
Adenosine deaminase
An enzyme that converts adenosine to inosine (and deoxyadenosine to deoxyinosine). Lack of adenosine deaminase causes immune deficiency.
Similarly, both acute activation 176 144 . The opposing effects of adenosine signalling at different stages of disease clearly represent a major challenge for drug development.
The causes of such opposing and/or timedependent effects are one of the central questions in this field. The opposite effects of adenosine receptor activation at differ ent stages of various disorders could reflect the complexity of adenosine receptor signalling on various cell types; each of these receptors can have a detrimental or protec tive effect depending on the nature of the tissue injury and associated pathological conditions. A major challenge in developing effective therapeutic strategies targeting adenosine receptors is to decipher these complex actions of adenosine receptors at the level of cellular and tissue specificity as well as disease progression, and to define the specific interactions between adenosine receptors and other neurotransmitter receptors. Moreover, other signalling molecules -such as other neurotransmitters in the brain -can further complicate this interaction. In the case of opposite effects on lung injury by Adora2b knockout and Nt5e knockout, A 2B receptordependent regulation of IL6 production was identified as a poten tial mechanism involved in the diminished pulmonary fibrosis seen in Adora2bknockout mice 175 .
In the brain, a switch between a protective versus damaging effect of A 2A receptors has been shown to be associated with the local interactions between adenosine and glutamate. In response to various brain injuries, extra cellular levels of adenosine as well as glutamate increase rapidly (within minutes) and dramatically (up to 100fold) owing to their presynaptic release from neurons and to the exocytosis and possible reversal of glutamate uptake from astrocytes 181, 182 . Remarkably, increasing the local levels of glutamate redirected A 2A receptor signalling from the PKA to the PKC pathway, thus switching the effect of A 2A receptor activation from antiinflammatory to proinflammatory 117 . This glutamate-A 2A receptor interaction can also be demonstrated in vivo in a cortical impact model of traumatic brain injury in mice. Thus, extrasynaptic glutamate levels can control the effect of A 2A receptor activation both in vivo and in vitro, switch ing it from antiinflammatory and neuroprotective to pro inflammatory and cytotoxic 117 . Such findings may explain -at least in part -the opposing effects of A 2A receptor ligands on tissue injury by demonstrating that the effects of A 2A receptors in brain injury are contextdependent as they can be influenced by local glutamate levels.
Tolerance to adenosine receptor ligands. Another find ing, possibly related to the cases described above, is that repeated exposure to adenosine receptor ligands (particularly to A 1 receptor ligands and caffeine) leads to the rapid development of tolerance, which is evident in both motor and cardiovascular responses 183, 184 . In some cases, repeated or prolonged exposure even results in the development of opposite effects, as seen with caffeine exposure in various neuronal injury models; although acute caffeine exposure exacerbates tissue injury, chronic caffeine administration usually has a protective effect 183, 184 . The mechanism underlying this desensitiza tion is not clear.
Similar paradoxical effects of acute versus chronic treatment have been reported for A 1 receptor agonists and antagonists 185 . Acute treatment with A 1 receptor agonists has a protective effect in brain injury, whereas chronic treatment increases ischaemic brain injury in rodents [185] [186] [187] . A 2A receptor agonists also induce desensi tization after prolonged treatment in cultured cells, as a result of the binding of the carboxyl terminus of the A 2A receptor to Factin crosslinking protein (also known as αactinin), which promotes A 2A receptor internaliza tion 188, 189 . Conversely, unlike caffeine, selective A 2A recep tor antagonists do not induce the rapid development of tolerance; motor responses to A 2A receptor antagonists did not decline even after 1 week of repeated treatments in an animal model of Parkinson's disease 190, 191 . This finding is encouraging for the current development of A 2A receptor antagonists for neurodegenerative disorders, which would require chronic treatment for several years.
Distinct effects of adenosine signalling in different cellular elements. Targeting the same receptor in different cells within the same tissue can induce fundamentally differ ent outcomes. One approach that can be applied to iden tify distinct functions of adenosine receptors in different cells within a tissue is to develop cellspecific conditional knockout models of individual adenosine receptor encoding genes using the Cre-loxP system 6 . Brainregion specific as well as cellspecific Adoraknockout mice are currently available (reviewed in REF. 47 ). Regional deletion of Adora2a genes has been achieved in the entire fore brain (that is, the striatum, cortex and hippocampus) 192, 193 or only in the striatum 194 . In addition, local deletion of the Adora1 gene in hippocampal CA1 or CA3 neurons and the Adora2a gene in the nuclear accumbens has been attained by the local injection of adenoassociated virus (AAV) vectors containing the Cre transgene into the brains of mice expressing adenosine receptorencoding genes in which a critical exon is flanked by loxP sites 195 . This strategy allowed for a temporal and regional speci ficity that has uncovered previously underexplored or underappreciated functions of adenosine receptors. For example, using local infection with AAV vectors carry ing short hairpin RNA targeted to produce sitespecific silencing of the Adora2a gene, we examined the specific role of A 2A receptors in the basal ganglia in the modula tion of the sleep-wake cycle and demonstrated that the arousal effect of caffeine is mediated by A 2A receptors in the nuclear accumbens shell 10 . Similarly, conditional knockout of Adora2b genes using the Cre-loxP system has been developed -for example, with selective deletion of the Adora2b gene in vascular endothelial cells 6 . In addition, several other recent technological advances allow systemslevel study of GPCR function in freely behaving animals. These include specific local modulation of neuronal activity using geneti cally engineered optical switches (for example, channel rhodopsin) 196, 197 as well as reversible silencing (for example, nonmammalian chloride channels) 198 and activation (for example, stimulatory GPCRs) 199, 200 of neurons. Applying these technical advances to the study of adenosine recep tors will provide a new level of understanding of adenosine receptor function and could facilitate the development of adenosine receptortargeting drugs.
Different effects in developing and mature individuals.
Another potential complication is the differential effects of adenosine receptor activation (or inactivation) at dif ferent stages in development. For example, studies in immature mice (7 days old) exposed to hypoxic brain injury indicate that A 2A receptor signalling has a protec tive role 201 , whereas studies in adult mice in which the Adora2a gene is knocked out suggest that this receptor has a harmful effect in brain ischaemia during adult hood 57 . Indeed, many studies in adult mice support the use of A 2A receptor antagonists to treat brain ischae mia 62, 202, 203 . There is some evidence for similar differen tial effects of A 1 receptors. Thus, in newborn mice, A 1 receptor agonism appears to have a deleterious effect in response to hypoxiainduced brain (white matter) injury 204 , whereas in adult mice it has a protective effect. The underlying reason for this could be that there are differing mechanisms mediating neuronal damage in the immature and mature brain.
Adenosine receptor heterodimerization.
There are reports showing that adenosine receptors -like other class A GPCRs -can undergo homo and heterodimeriza tion or even oligomerization. For example, a heterodimer composed of an A 2A receptor and a D 2 receptor has been observed in cultured cells as well as in the striatum of intact animals 2, [205] [206] [207] . It has been suggested that some of the pharmacological differences in A 2A receptor antago nists (that were tested for antiparkinsonian effects in an animal model of Parkinson's disease) may be correlated with differences in receptor heterodimerization (A 2A -D 2 versus A 2A -A 1 ) at postsynaptic and presynaptic sites 208, 209 . Moreover, it was recently suggested that the presence of the A 2A receptor may be important for the proper target ing of A 2B receptors to cell surface membranes, through the formation of A 2A -A 2B receptor heterodimers 210 . Given that adenosine receptors can be coimmuno precipitated with many different GPCRs even in the same cell and definitely in the same tissue, this represents a major challenge [211] [212] [213] . However, these results have not yet been confirmed in vivo and there are numerous reports indicating unequivocally that monomeric receptors are sufficient to induce signalling 214 . Therefore, until it is demonstrated that GPCR heterodimerization occurs in intact animals and that it confers major pharmacological consequences, we suggest that this additional potential complexity should not yet be taken into account for drug development.
Implications of widespread caffeine use. The methylxan thine caffeine is undoubtedly the most widely consumed psychoactive substance. It is estimated that the majority of the world's adult population consumes caffeine in suf ficient doses to influence behaviour on a daily basis 184 . It was realized many years ago that methylxanthines antagonize adenosine receptors and it is now accepted that many of the actions of caffeine are due to its effect of reducing the number of adenosine receptors to half the normal levels 215 . Nonetheless, the fact that longterm caffeine use is not associated with increased morbidity, and the fact that mice with reduced numbers of receptors fare well, strongly suggests that even the longterm use of drugs that block adenosine receptors can be safe.
Substantial adenosine receptor antagonism has already been achieved in so many people via their daily consump tion of caffeinecontaining beverages; this complicates the interpretation of drug trials studying adenosine receptor targeted agents. A novel adenosine receptor antagonist must therefore be proven to confer benefit over and above that provided by readily available and lowcost caffeine. Caffeine use in humans is limited by effects that are independent of adenosine receptor blockade. Even at the receptor that is most readily blocked by caffeine -the A 2A receptor -it is difficult to achieve as much as 50% occupancy. It can be calculated that the daily consumption of three to four regular cups of coffee results in approxi mately 50% A 1 and A 2A receptor occupancy for several hours 184 . This conclusion is supported by genetic studies in mice: heterozygous Adora1 and Adora2knockout mice (that is, mice in which there is a 50% reduction in the expression of A 1 and A 2A receptors) recapitulate some of the effects associated with longterm caffeine use 215 . A more selective antagonist therefore has the potential of affording more complete blockade and hence -at least in theory -a larger therapeutic benefit.
A clinical trial must very carefully assess the caffeine intake of each person enrolled in the study, as a trial in which the participants do not consume caffeine would not be a representative patient sample, and individuals who have recently refrained from caffeine use would encounter other issues, including relief from some of the (albeit weak) abstinence symptoms.
Caffeine use in the general population provides important clues to the potential therapeutic indications of adenosine receptor antagonists. Recent casecontrol and prospective studies have linked caffeine consump tion with a reduced risk of Parkinson's disease 216, 217 , dementia and Alzheimer's disease [218] [219] [220] , type 2 dia betes 221, 222 and chronic liver cirrhosis 221 . In addition, the common use of caffeine for the treatment of apnoea in premature infants has been associated with reduced retinopathy in 2year followup studies 223, 224 . This has prompted the investigation of A 2A receptormediated control of retinal vascularization in the developing eye and the involvement of these receptors in oxygen induced retinopathy in an animal model of retinopathy of prematurity 11 . Similarly, since 2000, at least five large prospective studies have firmly established a relationship between increased caffeine consumption and a decreased risk of developing Parkinson's disease; the initial study 20, 228 . Therefore, pharmacokinetic and pharmacodynamic (PK/PD) interactions between caffeine and adenosine receptor ligands may contribute to the varying responses to an adenosine receptorbased drug in clinical trials
. Indeed, PK/PD analyses show that recent caffeine ingestion (equivalent to two to four cups of coffee) affects A 2A receptor agonistinduced myocardial perfusion imaging 229 and reduces the efficacy of adenosine in the treatment of paroxysmal supraven tricular tachycardia 230 . In this regard, it is somewhat surprising that several current clinical trials of adenosine receptor antagonists have not taken caffeine consump tion into consideration in their clinical trial designs. For example, several recent Phase III clinical trials of the A 2A receptor antagonist istradefylline (KW6002) and preladenant (SCH420814) in patients with advanced
Parkinson's disease apparently did not include data on caffeine consumption 139, 227, [231] [232] [233] [234] [235] [236] . We speculate that if caf feine consumption is taken into consideration in clinical trials, we may see a clearer and better clinical response to adenosinebased drugs in smaller patient popula tions. Thus, in our view, careful consideration of caffeine pharmacology should be incorporated into most clinical trial programmes of adenosine receptorbased therapies to address this 'elephant in the room' in clinical studies. Genetic studies involving caffeine may offer a unique opportunity for identifying useful pharmacogenetic markers to predict individual responses to caffeine and adenosine drugs in clinical trials
Alternative therapeutic approaches Indirect receptor targeting. Adenosine receptors are found on many cells in the body, so exogenous adeno sine agonists pose a substantial risk of inducing side effects. As adenosine itself is rapidly degraded and does not readily pass the blood-brain barrier, it can be given acutely -for example, to regulate cardiac rhythm. Adenosine receptor ligands that are metabolically more stable would be able to reach all receptors and, because of their generally high affinity, would provide prolonged stimulation. Alternatively, instead of directly target ing adenosine receptors, one could raise the levels of endogenous adenosine. This approach could provide some degree of tissue specificity, but this has not yet been systematically investigated. [264] [265] [266] , anxiety and panic attack [267] [268] [269] . Single nucleotide polymorphisms (SNPs) in ADORA2A have been found to be associated with the age of onset of Huntington's disease 270 and with a reduced risk of Parkinson's disease 271 . The strongest associations between caffeine and Parkinson's disease were found among slow metabolizers of caffeine who were homozygous carriers of the CYP1A2 polymorphisms. In 2011, the first GWAS was carried out on coffee consumption in eight Caucasian cohorts comprising >18,000 individuals of Northern European ancestry 272 ; the top findings were further replicated in ~8,000 additional independent individuals. Two SNPs located in the 23-kb-long commonly shared 5ʹ flanking regions between the CYP1A1 and CYP1A2 genes (rs2470893 and rs2472297) were replicated in the follow-up studies with genome-wide significance. Also, in 2011 the first genome-wide association and interaction study (GWAIS) was performed by the NeuroGenetics Research Consortium to identify genes that influence the inverse association of caffeine consumption with the risk of developing Parkinson's disease 273 , and this study found that the SNP rs4998386 and neighbouring SNPs in GRIN2A (which encodes NMDA (N-methyl-d-aspartate) glutamate receptor subunit 2A) modulate the risk of developing Parkinson's disease in individuals who drink high amounts of coffee 273 . Together, these findings have provided a genetic basis for the individual variation in responses to caffeine and caffeine-related trials. This raises an exciting possibility of predicting the individual responses to caffeine (and possibly other adenosine receptor antagonists) through the identification of genetic polymorphisms of the associated alleles identified by these studies. It was recently demonstrated for the first time that the antiplatelet effect of a P2Y purinergic receptor 12 antagonist is influenced by the CYP2C19 genotype 274 . Given that caffeine and A 2A receptor antagonists have a common target and very similar pharmacological effects in the brain, the identification of these SNPs in association with caffeine consumption (in relationship to Parkinson's disease) led us to speculate that clinical trials might yield clearer outcomes if patients are subdivided and analysed by their genotypes for ADORA2A, neuronal cell adhesion molecule (NRCAM) GRIN2A, CYP1A1 and CYP1A2 genes. Thus, these studies not only provide proof of concept that taking caffeine consumption into consideration can help identify genes that are missed in GWAS, but they also offer a unique opportunity for personalized medicineidentifying useful pharmacogenetic markers for predicting individual responses to caffeine in Parkinson's disease populations in clinical trials.
Historically, drugs such as dipyridamole and metho trexate have been found to increase levels of endogenous adenosine. At present, clinical trials are being carried out to increase extracellular adenosine levels in humans. For example, the adenosine uptake inhibitor dipyri damole is used in patients for pharmacological stress echocardiography (as a coronary vasodilator) or as an inhibitor of platelet aggregation. However, dipyridamole could be easily used for enhancing the beneficial effects of adenosine receptors in other biomedical conditions, such as acute kidney injury, myocardial ischaemia or colitis 6 . An FDAapproved adenosine deaminase inhibi tor, deoxycoformycin (Nipent; Astex Pharmaceuticals), can increase extracellular adenosine levels and is cur rently in clinical use for the treatment of haematologi cal malignancies 237 . However, the production of the cytotoxic 2deoxyadenosine owing to the inhibition of adenosine deaminase is likely to contribute to this thera peutic outcome.
Allosteric enhancers.
Another possibility is to use socalled allosteric enhancers. This approach was first described for the A 1 receptor 238 when an allosteric enhancer was used to increase the responsiveness of this receptor to endogenous adenosine at sites of its pro duction. At the molecular level, an allosteric enhancer amplifies the action of agonists by stabilizing the ternary complex formed by the agonist, the adenosine recep tor and the G protein, thus minimizing the side effects of the drug. At least theoretically, the ability to target the receptor at two sites might increase tissue specific ity because the drug would act in concert with locally increased adenosine under pathological conditions and have little effect on sites where there are low basal adenosine levels. The recent identification of allosteric regulatory sites such as sodium and water control sites by GPCR crystal structure studies 239 has provided a detailed atomic structural framework that can substantially assist the biochemical identification and analysis of allosteric sites on adenosine receptors.
Multiple target drugs for adenosine signalling. The redundancy of adenosine receptor signalling, as revealed by studies in single Adoraknockout mice, indicates that targeting multiple steps and pathways involved in adenosine receptor signalling (such as adenosine gen eration and metabolism as well as adenosine receptors themselves) may be synergistic and more efficacious than targeting an individual step or pathway. A few multidrug target approaches involving the modulation of adenosine receptor signalling have been postulated and developed. For example, a single drug with dual actions -A 2A receptor antagonism and monoamine oxidase B inhibi tion -is expected to offer potential synergistic effects on neuroprotection and possible motor stimulation in Parkinson's disease 240 . Similarly, a new drug -T111 -that exhibits a dual action composed of adenosine transport (equilibrative nucleoside transporter 1; ENT1) inhibition and A 2A receptor agonism has been developed and tested to show its efficacy in an animal model of Huntington's disease 241 .
Another elegant use of network pharmacology is the development of a novel type of prodrug based on our understanding of the ATPdependent adenosine signal ling cascade 242 . In this approach, 5ʹphosphate prodrugs of A 2A receptor agonists are prepared that are preferably cleaved at sites of inflammation where NT5E is highly expressed to release the active A 2A receptor agonists 243 . This prodrug approach not only allows the sitespecific action of the A 2A receptor within the tissues where NT5E is enriched but also avoids the potent hypotensive effect of A 2A receptor agonists -a major limiting factor in their development.
Signalling pathway-biased drugs. Adenosine receptor activation can trigger alternative signalling pathways via different coupling and by functional interactions with a broad range of other GPCRs and signalling mol ecules 244 . The functional selectivity of different signalling pathways offers a new opportunity for developing sig nalling pathwaybiased drugs that selectively activate a specific intracellular adenosine receptor signalling pathway that is essential for a particular biological func tion. By systematically screening compound libraries of GPCRs for this 'biased' form of signalling, β-arrestin biased D 2 receptor ligands were successfully identified 245 and the discovery of a βarrestinbiased A 1 receptor ligand was also attempted, albeit with limited suc cess 246 . New knowledge of the diversity and modularity of GPCR structures, the A 2A receptor in particular, from a recent structural biology crystallization study offers opportunities to target receptor structures with different signalling functions 239 . The structure of the A 2A receptor in several functional states was recently described [247] [248] [249] , revealing that the A 2A receptor antagonist ZM241385 binds in an extended conformation perpendicular to the plane of the membrane bilayer 249 , whereas A 2A recep tor agonists bind in parallel to the plasma membrane, similarly to retinal rhodopsin 248 . Moreover, the allos teric regulatory site (such as sodium and water control sites) was recently identified 239, 250 . It is our hope that these exciting results will help in the rational design of novel drugs targeting specific signalling pathways and functions of A 2A receptors as well as other adenosine receptors 251 .
Conclusions
Over the past 80 years, evidence has accumulated to show that extracellular adenosine is an important modu lator of physiological and pathological processes. It has emerged that adenosine receptors can be safely targeted by drugs, and it is possible to generate highly specific agonists and antagonists of adenosine receptors. As a result, increasing numbers of clinical trials testing novel adenosinebased drugs in various indications have been initiated during the past decade. Although adenosine is present in virtually all cells, levels of endogenous adeno sine are sufficient to activate adenosine receptors only where they are most abundant. Activation of adenosine receptors has the potential to be beneficial in the treat ment of various inflammatory and autoimmune dis orders, pain, arrhythmia as well as sleep disorders and
Allosteric enhancers
Allosteric modulators do not have any activity by themselves, but as they bind to the allosteric site (which is distinct from the primary ligand binding orthosteric site) they can alter the receptor confirmation by an orthosteric ligand in such a way that the response to it is increased.
Equilibrative nucleoside transporter1
(ENT1). A channel located in the cell membrane; along with ENT2, ENT1 speeds up the bi-directional transport of adenosine across the cell membrane along its gradient.
Functional selectivity
Also known as biased signalling; an emerging concept of G protein-coupled receptor (GPCR) function. For example, some GPCR ligands preferentially activate signals via β-arrestins, others via G proteins.
β-arrestin
An adaptor protein that was initially recognized as a negative regulator of G protein signalling but is now recognized to be a multifunctional adaptor that can not only mediate G protein-coupled receptor (GPCR) internalization and desensitization but also produce distinct intracellular signalling and hence functional consequences. some metabolic disorders. However, given the wide spread distribution of adenosine receptors, agonists of these receptors can have effects in most tissues and pro duce a variety of responses, which makes them difficult to use. Targeting adenosine receptors indirectly using drugs that enhance endogenous local adenosine produc tion or reduce adenosine degradation may have more general applicability.
Adenosine receptor antagonists will have a larger effect where adenosine receptor activation is enhanced -for example, in various pathological processes, including several instances of local reduction of blood flow or local tissue destruction. However, several large Phase III clinical trials of A 2A receptor antagonists exhib ited insufficient clinical efficacy, despite convincing data from animal models and suggestive evidence from epi demiological studies of caffeine. These Phase III trials did, however, reveal a good safety profile of A 2A recep tor antagonists 138, 139 , as also indicated from caffeine use. By contrast, a large Phase III trial with an A 1 receptor antagonist failed because of its toxicity 144, 252 , but it is not yet known whether this is a class effect. Activation (or blockade) of adenosine receptors can have very different effects in different cells within the same tissue. Moreover, adenosine receptordirected pharmacotherapy can have different consequences in different stages of a disease process. A deep understanding of both the disease pro cess being targeted and the complexity of adenosine signalling in different cellular elements and different disease courses is crucial.
There are several factors that need to be explored: examination of adenosine receptor function -globally or locally -in disease models, particularly humans; the careful dissection of the site of action of drugs through their administration in animals with cellspecific recep tor deletions; careful examination of adenosine signal ling and the effects of the drug over the continuum of specific disease courses (for example, acute and chronic stages of a disease); clinical studies in which individual differences are carefully monitored and related to back ground factors such as caffeine use; and the examina tion of the possibility of combining direct adenosine receptor actions with drugs targeting other pathways and/or targets. We anticipate that these considerations will move the field forward and, over the next decade, facilitate the introduction of several additional clinical applications of adenosine receptortargeting treatments into the clinical setting. 
